Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Pimicotinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Pimicotinib is a once-a-day capsule for tenosynovial giant cell tumour (TGCT), a rare, locally aggressive tumour that grows in or around a joint and causes swelling, stiffness and pain. It was discovered and developed by Abbisko Therapeutics in Shanghai and is commercialised worldwide by Merck KGaA, Darmstadt, Germany. In China it is sold as 贝捷迈® (pimicotinib hydrochloride capsules).
China's National Medical Products Administration (NMPA) approved it in December 2025, the first approval anywhere in the world, for:
It is a prescription tumour medicine and should only be used under an orthopaedic oncologist, sarcoma specialist or medical oncologist.
In TGCT, a small number of tumour cells make too much of a signalling protein called CSF-1. It acts like a magnet, drawing in large numbers of inflammatory cells that carry the CSF-1 receptor (CSF-1R), and these make up most of the swelling. Pimicotinib is a highly selective CSF-1R blocker. By cutting that signal, it starves the tumour of the cells that build it up, so the mass shrinks and the joint can move more freely.
The global phase 3 MANEUVER trial, published in The Lancet in 2026, enrolled 94 adults with TGCT from China, Europe, the US and Canada whose tumours could not be removed safely by surgery. They were randomly given pimicotinib or a dummy capsule (placebo) for 24 weeks.
The specialist confirms the exact dose and how to take it using the Chinese prescribing information.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
In the 24-week placebo-controlled part of MANEUVER, side effects were mainly mild, and only 1 of 63 patients (2%) stopped treatment because of them.
Serious side effects occurred in 3 of 63 patients (4.8%) on pimicotinib and 1 of 31 (3.2%) on placebo. It is approved for adults only. Tell your doctor about all other medicines you take, and if you are pregnant, planning a pregnancy or breastfeeding, so they can check the full Chinese prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval and is not sold in Indian pharmacies. In the US, the FDA has accepted the application for review (January 2026), but it has not been approved there yet, and we found no European Medicines Agency approval.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. We also help import Romvimza, another CSF-1R medicine used for TGCT.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The capsules travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on the pack. As this is a daily, long-term treatment, we plan repeat orders in advance so there is no gap in supply. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or treating hospital on a valid specialist's prescription.
Orthopaedic oncology and sarcoma teams in Delhi see TGCT patients from across North India, close to our New Delhi dispatch point.
Patients in Mumbai can send the specialist's prescription with MRI and biopsy reports, and the capsules are delivered as advised.
A written quote is shared first, so patients can plan for months of daily treatment.
Chennai's bone and soft-tissue tumour units can request the medicine for a named patient.
We schedule repeat orders ahead of time so daily dosing is never interrupted.
Supplies to Kolkata and the eastern states are tracked from dispatch to delivery.
Patients in Pune can use the same documented import route, with updates at every stage.
The treating specialist can share the prescription and the reason surgery is not advised to start the request.
Patients treated at hospitals in Vellore can have their supply sent to the hospital pharmacy or home.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating centre.
We coordinate delivery to orthopaedic and cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the capsules in Kochi and nearby cities, with the import papers handled for them.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
